ZNF750 exerted its Antitumor Action in Oral Squamous Cell Carcinoma by regulating E2F2

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• E2F transcription factor 2 (E2F2) is a cell cycle activator implicated in tumor development and metastasis.
• Previous studies indicated E2F2 is significantly reduced by Zinc-finger protein 750 (ZNF750) in oral squamous cell carcinoma (OSCC).
• The precise role of E2F2 in the antitumor effects of ZNF750 within OSCC remains to be fully elucidated.

Purpose of the Study:

• To investigate the involvement of E2F2 in the antitumor mechanisms of ZNF750 in oral squamous cell carcinoma.
• To determine how ZNF750 regulates E2F2 activity and its downstream targets related to proliferation and metastasis.

Main Methods:

• Establishment of a nude mouse xenograft model using CAL-27 cells with altered ZNF750 expression (oeZNF750 and shZNF750).
• Assessment of tumor growth, volume, and weight, alongside in vivo and in vitro analysis of E2F2, Ezh2, PHF19, and metastasis-related gene expression.
• Luciferase assays to evaluate ZNF750's regulatory effect on E2F2 activity and cotransduction experiments to study E2F2's impact on ZNF750's antitumor actions.

Main Results:

• ZNF750 significantly repressed tumor growth and metastasis, evidenced by reduced tumor size, weight, and expression of proliferation/metastasis genes.
• Knockdown of ZNF750 reversed these antitumor effects, while ZNF750 inhibited E2F2 luciferase activity.
• E2F2 partially counteracted ZNF750's antitumor effects, increasing self-renewal, invasion, migration, and Ezh2/MMP13 expression; conversely, silencing E2F2 enhanced ZNF750's efficacy.

Conclusions:

• ZNF750 exerts critical antitumor activity in OSCC by suppressing E2F2 activity.
• ZNF750 regulates transcriptional repressors, inhibiting OSCC cell proliferation and metastasis.
• Targeting E2F2 in conjunction with ZNF750 may offer a therapeutic strategy for OSCC.